Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.
NEW CLASS OF MEDICINES
Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.
CLINICAL STAGE PLATFORM
We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.
Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, cancer and liver diseases.